Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TOXIPLAT renal toxicity biomarker evaluation in cisplatin and/or ifosfamide-treated cancer patients
2007-004251-12Phase 4Active
- Sponsor
- Institut Claudius Regaud
- Start
- Sep 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cisplatin and ifosfamide in Non-hematologic malignancy, sponsored by Institut Claudius Regaud. Primary endpoints: Identification and evaluation of early biological markers of renal toxicity, Serum and urinary cystatin C and 4 more. Started Sep 2007; status: active.
02
Drugs
cisplatinifosfamide
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2007-004251-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004251-12.